Eastman Chemical Co (EMN) Earnings Surpass Estimates: 1Q Adjusted EPS Beats Expectations, Sales Revenue on Target

Eastman Chemical Co on Smartkarma

Analyzing Eastman Chemical Co on Smartkarma, Baptista Research‘s report titled “Eastman Chemical Company: Tackling Market Instabilities – A Strategy for Success! – Major Drivers” highlights a mixed performance in the previous quarter. While revenues fell short of analyst projections, earnings managed to exceed expectations. The decline in earnings was mainly attributed to volume and mix, leading to a variable margin decrease of around $450 million.

Despite these challenges, Eastman Chemical’s management remains cautiously optimistic about market stability, especially in non-discretionary sectors such as pharma and medical. They foresee some modest growth in these areas, indicating a strategic approach to navigating the current market environment.

A look at Eastman Chemical Co Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Analysts at Smartkarma have rated Eastman Chemical Co based on various factors that indicate its long-term outlook. The company scored well in Dividend, Growth, and Momentum, with scores of 4 for each. This suggests that Eastman Chemical Co is likely to provide steady dividends, grow consistently, and exhibit positive momentum in the market.

However, the company received lower scores in Value and Resilience, with scores of 3 and 2 respectively. This indicates that Eastman Chemical Co may not be considered undervalued compared to its peers and might have some vulnerability to economic downturns or market challenges. Overall, with a mix of strong and weaker scores, Eastman Chemical Co‘s long-term outlook appears to be a balance of growth potential and possible risks.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma